FDA Issues Warning Letter to BMC Medical for Unapproved CPAP Modifications and Safety Reporting Failures

The United States Food and Drug Administration (FDA) has issued a formal warning letter to Beijing-based BMC Medical Co Ltd, citing significant regulatory violations involving the unauthorized modification of sleep apnea devices and a failure to report critical firmware corrections aimed at preventing unexpected device shutdowns. The warning letter, dated May 20, 2026, follows a comprehensive inspection of the facilities of React Health Inc. (formerly 3B Medical Inc.), the primary U.S. importer and distributor of BMC Medical’s products. The regulatory action underscores the FDA’s increasing scrutiny of the sleep therapy market, a sector that has faced intense oversight following major industry recalls in recent years.

According to the federal agency, BMC Medical introduced modified versions of its Continuous Positive Airway Pressure (CPAP) and Auto-adjusting Positive Airway Pressure (APAP) systems into the U.S. market without obtaining the necessary premarket clearances. These devices, specifically the G3X APAP models, were found to have undergone substantial design and material changes that deviate from the original 510(k) clearance granted by the FDA in 2016. Furthermore, the agency highlighted a lapse in mandatory reporting regarding a firmware update designed to address a defect that caused devices to stop functioning during patient use, posing a direct risk to those suffering from obstructive sleep apnea (OSA).

Regulatory Violations and the 510(k) Clearance Process

The crux of the FDA’s warning centers on the legal classification of the G3X APAP devices as "adulterated" and "misbranded." Under the Federal Food, Drug, and Cosmetic Act, medical device manufacturers are required to submit a new premarket notification, known as a 510(k), whenever a device undergoes a modification that could significantly affect its safety or effectiveness.

The FDA’s investigation revealed that the G3X APAP was marketed as a new model but was based on the previously cleared Luna CPAP and Auto CPAP System. However, the modifications made to transition the device to the G3X model were extensive. These included updates to the device’s firmware and software algorithms, which introduced new recognition features for flow limitation, respiratory effort-related arousals (RERA), and periodic breathing. These algorithmic changes are designed to help the device distinguish between central and obstructive hypopnea events—a critical function for ensuring patients receive the correct pressure settings. The FDA noted that such changes fundamentally alter how the device classifies respiratory events, which directly impacts the clinical data provided to healthcare providers and the efficacy of the therapy itself.

In addition to software changes, the FDA identified physical modifications to the device’s hardware. Specifically, the sound abatement system—the component responsible for dampening the noise of the air pump—was modified. Because the sound abatement system is part of the "gas pathway" (the route through which air travels before being inhaled by the patient), any change in materials raises significant concerns regarding biocompatibility. The agency also noted that the printed circuit board assembly (PCBA) was updated with a new chip to handle the more complex algorithms. Collectively, the FDA determined that these changes necessitated a new regulatory review to ensure the device remained safe for consumer use.

Failure to Report Life-Safety Corrections

Beyond the unauthorized modifications, the FDA cited BMC Medical for a critical failure in its quality management and reporting systems. The agency discovered that certain Luna G3 APAP devices, running firmware version G3-2.00.76, were prone to unexpected shutdowns during therapy. For a patient with obstructive sleep apnea, a sudden loss of air pressure during sleep can lead to immediate hypoxia, fragmented sleep, and increased cardiovascular strain.

Internal records indicated that BMC Medical was aware of the defect and initiated a firmware correction (version G3-2.00.77) to remedy the shutdown issue. However, the company failed to notify the FDA of this "medical device correction" within the required 10-working-day window. The FDA classifies such corrections as actions taken to reduce a risk to health, and failure to report them is a violation of 21 CFR Part 806. As of late May 2026, the agency stated it had still not received the formal documentation required for this correction, despite the update being deployed to devices in the field.

Timeline of the FDA Investigation

The regulatory friction between the FDA and BMC Medical escalated following a physical inspection of React Health’s facility in Dublin, Ohio, in December 2025. React Health acts as the domestic representative and distributor for BMC Medical’s products in the United States. During this inspection, FDA investigators reviewed records that clarified the relationship between the two entities, establishing that Beijing-based BMC Medical is the "specification developer" and the legal owner of the 510(k) clearances.

• 2016: BMC Medical receives original 510(k) clearance for the Luna CPAP and Auto CPAP System.
• Post-2016: BMC Medical develops and implements modifications, leading to the creation of the G3X APAP and Luna G3 series.
• Late 2025: React Health’s Ohio facility is inspected by the FDA, revealing discrepancies in device models and unreported firmware fixes.
• May 19, 2026: The FDA confirms it has not received the mandatory report regarding the firmware correction for unexpected shutdowns.
• May 20, 2026: The FDA officially issues the warning letter to BMC Medical Co Ltd.

The agency has given BMC Medical 15 business days to respond in writing, detailing the specific steps the company has taken to correct the violations and prevent their recurrence. Failure to provide a satisfactory response could lead to more severe enforcement actions, including the seizure of products, injunctions against the company, or an import alert that would block BMC Medical products from entering the United States.

Background: The High-Stakes CPAP Market

The scrutiny of BMC Medical comes at a sensitive time for the sleep therapy industry. The global CPAP market has been in a state of upheaval since 2021, following the massive recall by Philips Respironics involving millions of devices. That recall was prompted by concerns that polyester-based polyurethane (PE-PUR) sound abatement foam could degrade and be inhaled or ingested by users, potentially causing toxic or carcinogenic effects.

The Philips recall created a significant vacuum in the market, allowing smaller manufacturers like BMC Medical and its U.S. partner React Health to expand their market share rapidly. However, this expansion has brought increased regulatory attention to the materials used in the "gas pathway" of all CPAP devices. The FDA’s focus on BMC’s sound abatement system modifications suggests that the agency is applying the lessons learned from the Philips crisis to ensure that no other manufacturer introduces untested materials into the air stream of respiratory devices.

Industry Implications and Analysis

The FDA’s warning letter serves as a reminder to the medical device industry that "software as a medical device" (SaMD) and firmware updates are subject to the same rigorous oversight as physical hardware. For manufacturers of sleep apnea technology, the distinction between a "minor update" and a "significant modification" is often a point of contention. However, the FDA’s stance is clear: if an algorithm change affects how a disease is diagnosed or treated—such as distinguishing between different types of hypopnea—it is a significant change that requires a new 510(k) submission.

For clinicians and patients, the warning letter raises concerns about the reliability of the data generated by these devices. If the algorithms used to track RERA and flow limitations have not been validated through the FDA’s clearance process, the accuracy of the "compliance reports" used by doctors to adjust patient treatment may be in question. Furthermore, the issue of unexpected shutdowns strikes at the core of patient trust in life-sustaining or life-improving home medical equipment.

Official Responses and Next Steps

As of the date of the warning letter’s publication, neither BMC Medical Co Ltd nor React Health Inc. has issued a formal public statement regarding the FDA’s findings. Requests for comment from both organizations have gone unanswered.

The path forward for BMC Medical involves a complex regulatory remediation process. The company must likely stop the distribution of the G3X APAP until a new 510(k) is submitted and cleared—a process that can take several months and requires extensive testing data. Additionally, they must audit their global reporting protocols to ensure that future firmware "bug fixes" that relate to patient safety are reported to regulatory bodies instantaneously.

For the broader medical device market, this event highlights the risks associated with the "specification developer" model, where the entity designing the device is located in a different jurisdiction than the entity distributing it. The FDA has signaled that it will hold international developers strictly accountable for the compliance of devices sold on American soil, regardless of where the engineering or manufacturing occurs.

As the 15-day deadline for a response approaches, the industry will be watching closely to see if BMC Medical can rectify its standing with the FDA or if this warning letter is the precursor to a larger market withdrawal. For now, the FDA advises healthcare providers and patients to remain vigilant and report any adverse events or device malfunctions through the MedWatch Safety Information and Adverse Event Reporting Program.